NUMERICAL STUDY OF DIFFERENCES IN THROMBOLYTIC THERAPY WITH MULTIPLE BLOOD RHEOLOGY MODELS IN REAL BIFURCATED VEINS

Venous thromboembolism (VTE) is a common cardiovascular disease, and numerical modeling based on computational fluid dynamics (CFD) is an important tool for thrombus therapy research. However, there are numerous rheological models of blood, and significant differences exist between multiple blood rheology models. Currently, the performance of differences between different blood rheology models has not been adequately investigated. In this study, we propose a bio-hydrodynamic model for the numerical study of venous thrombosis therapy, which takes into account the coupling between venous blood flow, vascular structure, and drug mass transfer, and considers blood as a fluid with different rheological properties, venous valves as a hyperelastic solid, and thrombus clots as a porous material. Numerical simulations were performed for both idealized and patient-specific vascular models, and the numerical results of thrombolytic therapy for venous thrombosis were comprehensively analyzed. The results showed that the patient-specific vascular model was closer to the actual vascular situation, which was affected by local features such as bifurcation and bending, with obvious flow velocity changes, higher vortex intensity and Pe number, and larger values of valve displacement. At the same time, the results of different hemorheological models were different. Under the patient-specific model, the Newtonian model had lower blood viscosity, higher flow velocity and Pe number, faster material transfer, and better thrombolytic performance; the most significant difference in performance was seen in the non-Newtonian model with Bingham fluid, which had higher blood viscosity values, smaller Pe number, and poorer thrombolytic performance. This study advocates the use of actual patient vascular models and consideration of the actual rheological properties of blood for the numerical study of venous thrombosis, in order to promote the advancement of digital and intelligent medical technology in the field of thrombosis treatment.